DISCLAIMER: FOR RESEARCH USE ONLY. The material provided is "as is", and using TOPOGRAPH is without warranties of any kind, either expressed or implied. The content provided by this resource CANNOT subsitute for clinical judgement or professional oncology advice. Improper use of this resource may lead to harm.
NOTE: The haematology contents of this resource is currently under review and in the process of being updated.
The content curators (FL & ST) have no financial conflict of interest to disclose.
Publications
Lin FP, Thavaneswaran S, Grady JP, Ballinger M, Kansara M, Oakes SR, Desai J, Lee CK, Simes J, and Thomas DM. Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology.npj Precis Oncol 2021; 5: 58. doi: 10.1038/s41698-021-00194-z
Lin FP, Thavaneswaran S, Grady JP, Napier CE, Kansara M, Sebastian L, Kee D, Oakes SR, Blackburn J, Scott HS, Glover A, Fox SB, Goldstein D, Leo P, Amanuel B, Desai J, Lee CK, Ballinger ML, Simes RJ, Thomas DM. Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.J Clin Oncol 40, 2022 (suppl 16; abstr 3073). doi: 10.1200/JCO.2022.40.16_suppl.3073
Lin FP, Thavaneswaran S, Napier CE, Grady JP, Kansara M, Sebastian L, Kee D, Zaheed M, Millward M, Brown MP, Charakidis M, Craft PS, Grimison PS, Harrup RA, O'Byrne KJ, Desai J, Lee CK, Ballinger ML, Simes RJ, Thomas DM. Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.J Clin Oncol 41, 2023 (suppl 16; abstr 1540). doi: 10.1200/JCO.2023.41.16_suppl.1540
Lin FP, Grady JP, Napier CE, Callow M, Thavaneswaran S, Huang ML, Zaheed M, Kansara M, Sebastian L, Ballinger ML, Simes RJ, Thomas DM. Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board.J Clin Oncol 42, 2024 (suppl 16; abstr 1557). doi: 10.1200/JCO.2024.42.16_suppl.1557
The Australian Genomic Cancer Medicine Program (Omico Ltd.) acknowledges funding support from the Australian Federal Government and Office for Health and Medical Research (NSW, Australia).
F.P.L. gratefully acknowledges support from the philanthropic fund of the Wolf family, Professor Richard Epstein, and the Kinghorn Centre for Clinical Genomics for the initial phase of this work, as well as current funding support provided by a Medical Research Future Fund (RARUR000125) and a Capacity Building Grant from the Cancer Institute New South Wales (2021/CBG003).
